Примери за използване на Combination with ipilimumab на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
For symptomatic hyperthyroidism, nivolumab or nivolumab in combination with ipilimumab should be withheld and antithyroid medication should be initiated as needed.
whether it is used alone or in combination with ipilimumab.
OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced(unresectable or metastatic) melanoma in adults.
Nivolumab in combination with ipilimumab should be discontinued for life-threatening
When nivolumab is administered in combination with ipilimumab, refer to the Summary of Product Characteristics for ipilimumab prior to initiation of treatment.
For symptomatic diabetes, nivolumab or nivolumab in combination with ipilimumab should be withheld, and insulin replacement should be initiated as needed.
Nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued for severe(Grade 3) or life-threatening(Grade 4) adrenal insufficiency.
Severe rash has been observed with nivolumab in combination with ipilimumab and, less commonly, with nivolumab as monotherapy(see section 4.8).
For symptomatic hypothyroidism, nivolumab or nivolumab in combination with ipilimumab should be withheld, and thyroid hormone replacement should be initiated as needed.
Permanent discontinuation of treatment was required in a greater proportion of patients receiving nivolumab in combination with ipilimumab than in those receiving nivolumab monotherapy.
Nivolumab or nivolumab in combination with ipilimumab should not be resumed while the patient is receiving immunosuppressive doses of corticosteroids or other immunosuppressive therapy.
A fourth study in 945 previously untreated advanced melanoma adult patients investigated Opdivo in combination with ipilimumab, Opdivo used alone or ipilimumab used alone.
Frequency: Not known for nivolumab monotherapy/ nivolumab in combination with ipilimumab[Table key:
In intermediate/poor-risk patients, OS benefit was observed in the nivolumab in combination with ipilimumab arm vs. sunitinib regardless of tumour PD-L1 expression.
nivolumab or nivolumab in combination with ipilimumab should be withheld
OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma(see section 5.1).
There are no data on the use of nivolumab in combination with ipilimumab in patients with only a non clear-cell histology in first line RCC.
Nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued for any severe immune-related adverse reaction that recurs
The improvement in OS was similar between nivolumab in combination with ipilimumab and nivolumab monotherapy in patients with high tumour PD-L1 expression(PD-L1≥ 1%).